Skip to content
Peptilyze
Longevity & mitochondria

FOXO4-DRI studies

25 journal papers mention FOXO4-DRI in the title or abstract. Here are the most cited, the latest, and a few facts about the literature.

Studies range from laboratory work to clinical trials. A paper listed here is not an endorsement and says nothing about whether FOXO4-DRI is safe, effective or approved for any use.

Compare FOXO4-DRI prices, from €119.95 →

Papers
25
22 articles, 3 reviews
Earliest paper
2017
Most papers in 2026 (4)
Open access
72%
free to read somewhere
Reviews
12%
of all papers listed

What kind of studies

Of 19 papers in PubMed that mention FOXO4-DRI in the title or abstract, by the study type PubMed records. Categories overlap, so they do not add up to the total.

  • Randomized controlled trials0
  • Other clinical trials0
  • Meta-analyses and systematic reviews0
  • Other reviews5
  • Case reports0
  • Animal studies only5
  • Studies in humans9

Study types are tags assigned by publishers and PubMed indexers; very new papers are often not tagged yet, and a tag is not a quality rating. Retracted papers are excluded. Source: PubMed (NCBI).

Papers per year

2017 to 2026, peak 4 papers in a year. The latest year may still be incomplete.

2017: 3 papers2018: 0 papers2019: 1 papers2020: 2 papers2021: 3 papers2022: 3 papers2023: 3 papers2024: 2 papers2025: 4 papers2026: 4 papers20172026

Where it is published

  1. Naunyn-Schmiedeberg s Archives of Pharmacology2 papers
  2. Frontiers in Bioengineering and Biotechnology2 papers
  3. Cell1 papers
  4. Circulation1 papers
  5. Experimental Gerontology1 papers

The papers

Most citedName in the title

No papers in this list match the filter.

LatestName in title or abstract

  1. FOXO4 as a Redox-Sensitive Regulator of Antioxidant Defense and Cellular Senescence: Cysteine-Based Signaling, p53 Interaction, and Therapeutic Targeting

    Diana-Maria Mateescu, Dragos-Mihai Gavrilescu, Adelina-Raluca Marinescu et al. · Antioxidants · 2026

    ReviewOpen access · CC BYRead the open copy →

  2. Targeting the FOXO4-p53 axis by retro-inverso peptide senolytic agents: a pharmacological strategy to mitigate brain aging and cognitive decline

    Ayman Ali Mohammed Alameen, Hayder M. Al‐kuraishy, Mohamed N Fawzy et al. · Naunyn-Schmiedeberg s Archives of Pharmacology · 2026

    Review3 citations

  3. Cellular senescence in the aging and diseased kidney

    Floris A. Valentijn, Lucas L. Falke, Tri Q. Nguyen et al. · Journal of Cell Communication and Signaling · 2017

    ReviewOpen access · CC BY174 citationsRead the open copy →

Each list shows up to 40 papers.See all 25 on OpenAlex. Source: OpenAlex (CC0), journal articles and reviews with a DOI, retractions excluded, refreshed weekly, last 4 Nov 2026, 08:26 UTC. Papers are listed by their metadata only; follow the links to read them. A license shown on an open copy is the license the publisher or repository states for that copy.